What's in Store for Core Laboratories Stock in Q2 Earnings?
CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
Zacks Investment Research7/23/2026Neutral
CLB
Core Laboratories NVNYSEENERGYOIL & GAS EQUIPMENT & SERVICES
Key Statistics
Market Cap
$492.77M
P/E Ratio
18.43
EPS
$0.58
Beta
1.01
52W High
$20.33
52W Low
$9.70
50-Day MA
$12.30
200-Day MA
$15.36
Dividend Yield
0.36%
Profit Margin
5.53%
Forward P/E
19.76
PEG Ratio
1.67
About Core Laboratories NV
Core Laboratories NV (CLB) stands as a leading provider of specialized reservoir optimization services and products in the oil and gas industry, focusing on enhancing reservoir characterization and maximizing production efficiency. Leveraging advanced technologies and proprietary analytical methods, the company delivers innovative solutions that prioritize sustainability and environmental responsibility. With a strong global presence, Core Labs is strategically positioned to seize new growth opportunities and effectively navigate the challenges of an evolving energy landscape, making it a compelling choice for institutional investors seeking long-term value in the sector.
Fundamentals
| Revenue (TTM) | $524.73M |
| Gross Profit (TTM) | $104.54M |
| EBITDA | $60.57M |
| Operating Margin | 1.62% |
| Return on Equity | 11.10% |
| Return on Assets | 4.86% |
| Revenue/Share (TTM) | $11.35 |
| Book Value | $5.84 |
| Price-to-Book | 1.93 |
| Price-to-Sales (TTM) | 0.94 |
| EV/Revenue | 1.263 |
| EV/EBITDA | 9.66 |
| Quarterly Earnings Growth (YoY) | -31.60% |
| Quarterly Revenue Growth (YoY) | -1.40% |
| Shares Outstanding | $46.10M |
| Float | $45.45M |
| % Insiders | 1.43% |
| % Institutions | 113.81% |
Historical Volatility
HV 10-Day
44.15%
HV 20-Day
44.86%
HV 30-Day
50.05%
HV 60-Day
45.89%
HV Rank
57.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.50 target)
1
Strong Buy1
Hold1
Strong SellLatest News
Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline
Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/22/2026Negative
Core Stock Down 39% in 6 Months: Should You Hold or Sell Now?
CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.
Zacks Investment Research7/20/2026Negative
CORE LABORATORIES ANNOUNCES TIMING OF SECOND QUARTER 2026 EARNINGS RELEASE AND CONFERENCE CALL
HOUSTON, June 30, 2026 /PRNewswire/ -- Core Laboratories (NYSE: "CLB") will host its second quarter 2026 conference call for investors and analysts at 7:30 a.m. CDT / 8:30 a.m.
PRNewsWire6/30/2026Neutral
Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?
CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delayed shipments, limiting visibility into a stronger recovery.
Zacks Investment Research6/9/2026Negative
Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research5/29/2026Negative
Implied Volatility Surging for Core Laboratories Stock Options
Investors need to pay close attention to CLB stock based on the movements in the options market lately.
Zacks Investment Research5/21/2026Neutral
Core Laboratories Q1 Earnings Meet Estimates, Decline Y/Y
CLB's Q1 earnings meet estimates but fall Y/Y as a revenue miss and Middle East disruptions weigh on both key segments.
Zacks Investment Research5/4/2026Negative
Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript
Core Laboratories Inc. (CLB) Q1 2026 Earnings Call Transcript
Seeking Alpha4/30/2026Neutral
CORE LAB REPORTS FIRST QUARTER 2026 RESULTS
REVENUE OF $121.8 MILLION, DOWN 12% SEQUENTIALLY AND FLAT YEAR-OVER-YEAR OPERATING INCOME OF $1.9 MILLION; EX-ITEMS, $6.6 MILLION, DOWN 58% SEQUENTIALLY AND 44% YEAR-OVER-YEAR GAAP LOSS PER SHARE OF $0.02 ; EPS EX-ITEMS OF $0.06, DOWN 72% SEQUENTIALLY AND 58% YEAR-OVER-YEAR FREE CASH FLOW OF $0.5 MILLION NET DEBT INCREASED BY $3.9 MILLION; LEVERAGE RATIO AT 1.20 COMPANY REPURCHASED 51,781 SHARES OF COMMON STOCK, FOR $0.9 MILLION AGGREGATE PURCHASE PRICE COMPANY ANNOUNCES Q2 2026 QUARTERLY DIVIDEND HOUSTON, April 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported first quarter 2026 revenue of $121,800,000. Core's operating income was $1,900,000, with a loss per diluted share of $0.02, all in accordance with U.S. generally accepted accounting principles ("GAAP").
PRNewsWire4/29/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CLB and any ticker you trade — then tracks every position and per-strategy win rate.
More ENERGY Stocks
Data last updated: 7/29/2026